• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Verrica Pharmaceuticals Inc (NQ: VRCA )

    0.8299 +0.1256 (+17.83%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Verrica Pharmaceuticals Inc

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    This Super Micro Computer Analyst Turns Bearish; Here Are Top 5 Upgrades For Wednesday
    Via Benzinga
    Dow Jumps 400 Points; Yum! Brands Posts Downbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    S&P 500 Gains 1%; Vimeo Shares Spike Higher
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Why Palantir Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    10 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
    From Kahn Swick & Foti, LLC
    Via Business Wire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    This Tractor Supply Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
    Via Benzinga
    Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
    Via Benzinga
    Crude Oil Down Over 1%; Mercury Systems Shares Spike Higher
    Via Benzinga
    Exposures Fossil Fuels
    Dow Jumps Over 200 Points; Performance Food Group Shares Gain After Q4 Results
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
    VRCA stock results show that Verrica Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    US Stocks Mixed; Inflation Rate Falls More Than Projected
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday?
    Verrica Pharmaceuticals shares positive preliminary results from Part 2 of its Phase 2 trial for VP-315 in treating basal cell carcinoma, showing promising tumor reduction and safety. No serious... 
    Via Benzinga
    Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    7 Short-Squeeze Stocks That Could Beat Down the Bears
    Panic can be a cruel emotion, especially when the consequences are uncapped red ink. 
    Via InvestorPlace
    Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
    From Verrica Pharmaceuticals Inc.
    Via GlobeNewswire
    VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.